Pricey Pfizer Drug Spurs Call For NIH Collaboration Probe

Law360, New York (March 20, 2013, 6:58 PM EDT) -- Sen. Ron Wyden, D-Ore., on Tuesday urged the National Institutes of Health to study whether drugmakers are benefiting excessively from public-private partnerships aimed at developing new medicines, prompting a furious pushback from Pfizer Inc., whose newly approved rheumatoid arthritis treatment got a lift from taxpayer-funded research.

Wyden released a letter he sent to the NIH last week spotlighting the roughly $25,000-per-year price tag of Pfizer's Xeljanz, or tofacitinib, arguing that when government researchers play a role in drug development, pharmaceutical companies have an obligation to return...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.